Browsing by Autor "L. Dimier-David"

Now showing 1 - 7 of 7

[A new case of autochthonous visceral leishmaniasis in Bolivia].
(National Institutes of Health, 1991) L. Dimier-David; A. Inofuentes; María Hernández Carrasco; Catherine David; Franklin Vargas; Susana Revollo; Dedet Jp
A sixth autochthonous case of visceral leishmaniasis is reported in Bolivia. It is also the fourth case detected in the Yungas Valley (Department of La Paz) confirming the long-term existence of the disease in this area where cases of canine leishmaniasis and natural infestation of the phlebotomine sandfly, Lutzomyia longipalpis, were previously reported.
Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimonial compounds
(Oxford University Press, 1994) E Falcoff; N. J. Taranto; Carlos Remondegui; J. P. Dédet; Laëtitia Canini; C.M. Ripoll; L. Dimier-David; Fernando Regla Vargas; L. Gimenez; Jorge Guillermo Bernabó
In an open trial, longer courses of pentavalent antimonials (Sbv) at sub-optimal doses (10 mg/kg body weight), in association with recombinant human interferon-gamma (IFN-gamma) (100 micrograms/m2 of body surface area) were administered, by daily intramuscular injections, to 13 patients with diagnoses of cutaneous or mucocutaneous leishmaniasis unresponsive to Sbv. Four patients presented with large skin ulcers, and 9 had mucosal involvement as the main manifestation, the latter affecting the nose (3 cases), nose and septum (2 cases), nose and oral cavity (1 case), and nose, pharynx and larynx (3 cases). Except for one case with severe involvement of the upper respiratory tract, the lesions were fully resolved by the end of therapy (mean duration 40 +/- 12 [SD] d, range 30-60 d) in the 11 patients who completed therapy. The main side effects were headache and fever (7 cases), together with leucopenia and eosinophilia (4 cases). It is concluded that combined administration of low doses of Sbv plus IFN-gamma may provide a novel therapeutic approach for the treatment of antimony-resistant cutaneous or mucocutaneous leishmaniasis. The possible mechanisms by which IFN-gamma contributes to resolution of the disease are discussed.
Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study
(Oxford University Press, 1993) C. David; L. Dimier-David; Fernando Vargas; M Torrez; Jean-Pierre Dedet
This paper present the results of a retrospective study of cases of cutaneous and mucocutaneous leishmaniasis in Bolivia between 1975 and 1991. The total number of cases reported was 4058, 739 of which were mucous. Three different areas of endemic leishmaniasis are defined in Bolivia.
[Histopathology of mucocutaneous leishmaniasis caused by Leishmania (Vianna) braziliensis].
(National Institutes of Health, 1994) L. Dimier-David; P Ravisse; R Bustillos; F Rollano; F. Mallea; C. David; Philippe Lyèvre; L Valda; Jean-Pierre Dedet
A histopathological study of mucocutaneous leishmaniasis due to Leishmania (Viannia) braziliensis was carried out on 28 cutaneous and 114 mucosal biopsies, taken from Bolivian and Peruvian patients. This study showed similar histopathological findings in cutaneous and mucosal lesions. The cutaneous biopsies showed a strong epidermal hyperplasia occasionnally budding in the dermis. In the ulcerative area, the epidermis was totally necrosed and replaced by a fibrino-leucocytic edge. In the dermis, histio-lympho-plasmocytic infiltration was constantly found. The histiocytes often gathered in follicles sometimes with diffuse fibrosis. The parasites were encountered in 28.6 p. 100 of the biopsies. Whatever the mucosa concerned (i.e. nasal, palatal or lingual), the mucosal lesion was not different from the cutaneous lesion. The malpighian epithelium is either absent or the seat of a pseudo-epitheliomatous hyperplasia. Major histio-lympho-plasmocytic infiltration was found and extended through the depth of the lamina propria. Suppurative and fibrinoid necroses coexisted superficially and sometimes penetrated in depth. The parasites were found in about 30 p. 100 of the cases.
Isoenzyme characterization of Leishmania braziliensis braziliensis isolates obtained from Bolivian and Peruvian patients
(Oxford University Press, 1992) Susana Revollo; L. Dimier-David; C. David; Philippe Lyèvre; Clara Camacho; Jean-Pierre Dedet
Thirty-four Leishmania isolates obtained from Bolivian and Peruvian patients infected with mucocutaneous leishmaniasis were characterized by isoenzyme electrophoresis using 10 enzymatic markers; all belonged to the subspecies L.b. braziliensis. Three isolates showed marked variation compared with the reference strain with respect to 5 or 6 enzymes. These variant isolates originated from patients with forms of the disease which were unresponsive to treatment.
Parasitological diagnosis of mucocutaneous leishmaniasis due to Leishmania b. braziliensis in Bolivia
(Brazilian Society of Tropical Medicine, 1991) L. Dimier-David; Christophe David; P Ravisse; R Bustillos; Susana Revollo; Philippe Lyèvre; M Muñoz; Fernando Regla Vargas; Jean-Pierre Dedet
Parasitological diagnosis, using stained smears, culture and pathological examination of biopsy, was studied in 146 patients infected with mucocutaneous leishmaniasis, in Bolivia and Peru. The most efficient parasite detecting technique appeared to be the smear examination in cutaneous lesions (33% positive) and the pathology in case of mucous lesions (28% positive). In both, cutaneous and mucous lesions, the parasites were found most frequently in old lesions.
Rural campaign to diagnose and treat mucocutaneous leishmaniasis in Bolivia.
(National Institutes of Health, 1995) Jean-Pierre Dedet; R Melogno; Fernando Cárdenas; L Valda; C. David; Victoria Gallardo; M Torrez; L. Dimier-David; Philippe Lyèvre; M E Villareal
Mucocutaneous leishmaniasis (MCL) is endemic in the tropical Amazonian lowlands of Bolivia, an area that regularly receives influxes of migratory populations. In these new agricultural development areas, a campaign to diagnose and treat the disease was carried out between 1989 and 1992, in order to provide direct access to MCL treatment in the endemic areas at a standard equivalent to that offered in the urban centres in Bolivia. The campaign led to the creation of decentralized local centres for diagnosis and treatment of the disease. A campaign to inform the population about leishmaniasis was also undertaken and courses were run to educate medical and paramedical personnel. As a result of the campaign, 3285 cases of leishmaniasis were diagnosed, including 2152 cutaneous and 326 mucosal forms. Also, a total of 1888 cases were treated, 1677 of which cutaneous and 211, mucosal.